Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
Identifieur interne : 000957 ( PubMed/Corpus ); précédent : 000956; suivant : 000958Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
Auteurs : Margarita Pondal ; Connie Marras ; Janis Miyasaki ; Elena Moro ; Melissa J. Armstrong ; Antonio P. Strafella ; Binit B. Shah ; Susan Fox ; L K Prashanth ; Nicolas Phielipp ; Anthony E. LangSource :
- Journal of neurology, neurosurgery, and psychiatry [ 1468-330X ] ; 2013.
English descriptors
- KwdEn :
- Disruptive, Impulse Control, and Conduct Disorders (chemically induced), Dopamine Agonists (adverse effects), Female, Humans, Male, Middle Aged, Outpatient Clinics, Hospital (statistics & numerical data), Parkinson Disease (complications), Parkinson Disease (drug therapy), Retrospective Studies, Substance Withdrawal Syndrome (diagnosis).
- MESH :
- chemical , adverse effects : Dopamine Agonists.
- chemically induced : Disruptive, Impulse Control, and Conduct Disorders.
- complications : Parkinson Disease.
- diagnosis : Substance Withdrawal Syndrome.
- drug therapy : Parkinson Disease.
- statistics & numerical data : Outpatient Clinics, Hospital.
- Female, Humans, Male, Middle Aged, Retrospective Studies.
Abstract
Recently, symptoms similar to addictive drug withdrawal have been reported in a structured longitudinal study of patients with idiopathic Parkinson's Disease (PD) withdrawing from dopamine agonists (DA): the dopamine agonist withdrawal syndrome (DAWS).
DOI: 10.1136/jnnp-2012-302684
PubMed: 22933817
Links to Exploration step
pubmed:22933817Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.</title><author><name sortKey="Pondal, Margarita" sort="Pondal, Margarita" uniqKey="Pondal M" first="Margarita" last="Pondal">Margarita Pondal</name><affiliation><nlm:affiliation>Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada. mpondals@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name></author><author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name></author><author><name sortKey="Armstrong, Melissa J" sort="Armstrong, Melissa J" uniqKey="Armstrong M" first="Melissa J" last="Armstrong">Melissa J. Armstrong</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author><author><name sortKey="Shah, Binit B" sort="Shah, Binit B" uniqKey="Shah B" first="Binit B" last="Shah">Binit B. Shah</name></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name></author><author><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name></author><author><name sortKey="Phielipp, Nicolas" sort="Phielipp, Nicolas" uniqKey="Phielipp N" first="Nicolas" last="Phielipp">Nicolas Phielipp</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22933817</idno><idno type="pmid">22933817</idno><idno type="doi">10.1136/jnnp-2012-302684</idno><idno type="wicri:Area/PubMed/Corpus">000957</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000957</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.</title><author><name sortKey="Pondal, Margarita" sort="Pondal, Margarita" uniqKey="Pondal M" first="Margarita" last="Pondal">Margarita Pondal</name><affiliation><nlm:affiliation>Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada. mpondals@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name></author><author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name></author><author><name sortKey="Armstrong, Melissa J" sort="Armstrong, Melissa J" uniqKey="Armstrong M" first="Melissa J" last="Armstrong">Melissa J. Armstrong</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author><author><name sortKey="Shah, Binit B" sort="Shah, Binit B" uniqKey="Shah B" first="Binit B" last="Shah">Binit B. Shah</name></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name></author><author><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name></author><author><name sortKey="Phielipp, Nicolas" sort="Phielipp, Nicolas" uniqKey="Phielipp N" first="Nicolas" last="Phielipp">Nicolas Phielipp</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="eISSN">1468-330X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders (chemically induced)</term><term>Dopamine Agonists (adverse effects)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Outpatient Clinics, Hospital (statistics & numerical data)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Retrospective Studies</term><term>Substance Withdrawal Syndrome (diagnosis)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Substance Withdrawal Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Outpatient Clinics, Hospital</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recently, symptoms similar to addictive drug withdrawal have been reported in a structured longitudinal study of patients with idiopathic Parkinson's Disease (PD) withdrawing from dopamine agonists (DA): the dopamine agonist withdrawal syndrome (DAWS).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22933817</PMID><DateCreated><Year>2013</Year><Month>01</Month><Day>11</Day></DateCreated><DateCompleted><Year>2013</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.</ArticleTitle><Pagination><MedlinePgn>130-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2012-302684</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recently, symptoms similar to addictive drug withdrawal have been reported in a structured longitudinal study of patients with idiopathic Parkinson's Disease (PD) withdrawing from dopamine agonists (DA): the dopamine agonist withdrawal syndrome (DAWS).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objective of this study was to establish the frequency, predictors, and outcomes of DAWS in a movement disorders clinic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective chart review of a sample of patients with a clinical diagnosis of PD treated with DA in whom withdrawal or attempted withdrawal of DA was carried out because of adverse effects, or for any other reason. Out of 487 PD patient charts reviewed, 84 were withdrawn from the agonists and were evaluable.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirteen patients (15.5%) met criteria for DAWS (DAWS+) and 71 did not (DAWS-). DAWS developed upon withdrawal from pergolide, pramipexole and ropinirole, and did not respond to levodopa. DAWS outcomes included recovery in less than 6 months in 61%, in more than a year in 23%, and an inability to discontinue DA in 15% of patients. Development of impulse control disorders was the reason for DA withdrawal in all DAWS+, but only in 41% of DAWS- patients (p<0.0001). DAWS+ and DAWS- patients did not differ in other variables.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DAWS is a disabling complication of DA use. Critical features of the syndrome are the strong link with impulse control disorders, possibly the independence of DA dosage and type, and the resistance to treatment, including levodopa. Further studies are required to characterise those at risk as well as to define an effective treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pondal</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada. mpondals@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marras</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Miyasaki</LastName><ForeName>Janis</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Melissa J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Strafella</LastName><ForeName>Antonio P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Binit B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Prashanth</LastName><ForeName>L K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Phielipp</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):120</RefSource><PMID Version="1">22993451</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D007174" MajorTopicYN="N">Disruptive, Impulse Control, and Conduct Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010044" MajorTopicYN="N">Outpatient Clinics, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22933817</ArticleId><ArticleId IdType="pii">jnnp-2012-302684</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2012-302684</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000957 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000957 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22933817
|texte= Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22933817" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |